Keywords: Bayer, Adrea Biosciences, Dyax, BAY 86-9766, Pancreatic cancer, Antibody technology
Milestone payment for Ardea from Bayer, which executes license with Dyax
Article | 31 May 2012
USA-based Ardea Biosciences (Nasdaq: RDEA), which is currently the subject of a $1.26 billion takeover by AstraZeneca (The Pharma Letter April 23), ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
